347 related articles for article (PubMed ID: 33859650)
1. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
Front Immunol; 2021; 12():658753. PubMed ID: 33859650
[TBL] [Abstract][Full Text] [Related]
2. Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells.
D'Ippolito E; Wagner KI; Busch DH
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171940
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
Schwerdtfeger M; Benmebarek MR; Endres S; Subklewe M; Desiderio V; Kobold S
Curr Hematol Malig Rep; 2021 Apr; 16(2):218-233. PubMed ID: 33939108
[TBL] [Abstract][Full Text] [Related]
4. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath JA; Arber C
Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
[TBL] [Abstract][Full Text] [Related]
5. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
Holzinger A; Abken H
Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
[No Abstract] [Full Text] [Related]
6. The recent advancement of TCR-T cell therapies for cancer treatment.
Zhao X; Shao S; Hu L
Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):663-674. PubMed ID: 38557898
[TBL] [Abstract][Full Text] [Related]
7. An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies.
Chen L; Dong L; Ma Y; Wang J; Qiao D; Tian G; Wang M
BMC Immunol; 2021 Sep; 22(1):65. PubMed ID: 34583647
[TBL] [Abstract][Full Text] [Related]
8. The Anticancer Potential of T Cell Receptor-Engineered T Cells.
Ecsedi M; McAfee MS; Chapuis AG
Trends Cancer; 2021 Jan; 7(1):48-56. PubMed ID: 32988787
[TBL] [Abstract][Full Text] [Related]
9. Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.
Ren YB; Sun SJ; Han SY
Curr Pharm Des; 2018; 24(1):78-83. PubMed ID: 29283058
[TBL] [Abstract][Full Text] [Related]
10. TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential.
Poorebrahim M; Mohammadkhani N; Mahmoudi R; Gholizadeh M; Fakhr E; Cid-Arregui A
Cancer Gene Ther; 2021 Jun; 28(6):581-589. PubMed ID: 33654227
[TBL] [Abstract][Full Text] [Related]
11. Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.
Udyavar A; Geiger TL
Arch Immunol Ther Exp (Warsz); 2010 Oct; 58(5):335-46. PubMed ID: 20680493
[TBL] [Abstract][Full Text] [Related]
12. Re-adapting T cells for cancer therapy: from mouse models to clinical trials.
Stromnes IM; Schmitt TM; Chapuis AG; Hingorani SR; Greenberg PD
Immunol Rev; 2014 Jan; 257(1):145-64. PubMed ID: 24329795
[TBL] [Abstract][Full Text] [Related]
13. [T cell receptor-based immunotherapy: a review].
Chen Y; Gao GF; Tan S
Sheng Wu Gong Cheng Xue Bao; 2023 Oct; 39(10):4004-4028. PubMed ID: 37877387
[TBL] [Abstract][Full Text] [Related]
14. Adoptive cell transfer as personalized immunotherapy for human cancer.
Rosenberg SA; Restifo NP
Science; 2015 Apr; 348(6230):62-8. PubMed ID: 25838374
[TBL] [Abstract][Full Text] [Related]
15. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
16. The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
Arnaud M; Bobisse S; Chiffelle J; Harari A
Front Immunol; 2021; 12():701636. PubMed ID: 34394096
[TBL] [Abstract][Full Text] [Related]
17. Toll-Like Receptor-Based Strategies for Cancer Immunotherapy.
Pahlavanneshan S; Sayadmanesh A; Ebrahimiyan H; Basiri M
J Immunol Res; 2021; 2021():9912188. PubMed ID: 34124272
[TBL] [Abstract][Full Text] [Related]
18. Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy.
Xin G; Schauder DM; Zander R; Cui W
Immunotherapy; 2017 Sep; 9(10):837-849. PubMed ID: 28877635
[TBL] [Abstract][Full Text] [Related]
19. qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue.
Pullarkat S; Black G; Bleakley M; Buenrostro D; Chapuis AG; Hirayama AV; Jaeger-Ruckstuhl CA; Kimble EL; Lee BM; Maloney DG; Radich J; Seaton BW; Specht JM; Turtle CJ; Woolston DW; Wright JH; Yeung CCS
PLoS One; 2024; 19(6):e0303057. PubMed ID: 38843256
[TBL] [Abstract][Full Text] [Related]
20. Overcoming the toxicity hurdles of genetically targeted T cells.
Casucci M; Hawkins RE; Dotti G; Bondanza A
Cancer Immunol Immunother; 2015 Jan; 64(1):123-30. PubMed ID: 25488419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
